Leukæmia Antigens

Establishment of five human malignant non-T lymphoid cell lines and mixed lymphocyte-tumor reaction.

“…The autologous lymphocytes from patient MS. who was in CCR responded well to the mitomycin C-treated THP-6 cells, strongly suggesting the presence of leukemia-associated antigens on THP-6 cells. These findings seem to be in agreement with the data reported by other investigators that showed the presence of cell mediated immunity mediated by leukemia-associated antigens in the patients with ALL (Viza et al 1969;Halterman and Leventhal 1971;Powles et al 1971).…”

Response of remission lymphocytes to autochthonous leukaemic myeloblasts

“…Mixed and control cultures were set up as previously described, in both media. The results of experiments with remission lymphocytes from 3 patients (HH, JC and SW, all receiving I) obtained at further stages of treatment than in the previous experiments are shown in Table II Table I test cells in control culture (Fridman and Kourilsky, 1969;Viza et al, 1969;Powles et al, 1971). Although similar lymphocyte responses have been observed to cells from solid tumours (Ambus et al, 1974;Vanky et al, 1973) they are not restricted to neoplastic cells.…”

“…The evidence of such antigens specific to human leukaemic cells is based largely on observations that DNA synthesis by lymphocytes from patients in remission is stimulated by autochthonous acute-phase leukaemic blasts (Fridman and Kourilsky, 1969;Viza et al, 1969;Powles et al, 1971) though the existence of such antigens on lymphoblastic leukaemic cells using this test has been disputed (Schweitzer, Melief and Eijsvoogel, 1973).…”

Surface antigens in acute myeloblastic leukaemia: a study using heterologous antisera

“…Nevertheless, over the years there have been several reports of the production of heterologous antisera specific for leukaemia-associated antigens in acute myeloblastic leukaemia (AML) and other leukaemias (Garb et al, 1962;Hyde et al, 1967;Mann et al, 1971;Mann et al, 1974;Metzgar et al, 1972;Mohanakumar et al, 1974;Baker et al, 1974;Durantez et al, 1976). In addition, stimulation of lymphocyte blastogenesis 33 by leukaemic cells, particularly in the autologous situation (Fridman and Kourilsky, 1969;Viza et al, 1969;Powles et al, 1971;Taylor et al, 1976) and in HL-Aidentical siblings (Fefer et al, 1976) has been presented as evidence for the existence of these antigens. These findings have generated much interest in the possibility of exploiting these leukaemia antigens in active immunotherapy to prolong the duration of clinical remission in AML (Powles et al, 1973;Freeman et al, 1973;Powles et al, 1977).…”